AEON Biopharma, Inc.

AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company that went public through a de-SPAC merger with Priveterra Acquisition Corp, which traded on Nasdaq under the ticker PMGM and was sponsored by Priveterra Capital. Priveterra completed its SPAC IPO in 2021, targeting the healthcare and life sciences sector. The combined entity, focused on developing botulinum toxin therapeutics for conditions including cervical dystonia and gastroparesis, filed an 8-K with the SEC on July 5, 2023, reflecting material developments tied to the transaction. AEON Biopharma is currently a post-merger public company operating in the biopharma space. Sign up on SpacDesk for full filing history, sponsor profiles, and analytics on this deal and hundreds of other SPAC transactions.